Leerink Partners Rates Eli Lilly and (LLY) buy
Leerink Partners maintains its buy rating on Eli Lilly with a $1,232 price target, a 1.98% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Leerink Partners rated Eli Lilly and Company ($LLY) "buy" with a $1,232 price target on June 25, 2026.
Since the rating, $LLY is up 7.7% after 1 week, up 6.2% after 1 month and up 11.6% to date (from the $1,126.08 close on Jun 25, 2026).
LLY
Eli Lilly and Company
Key Points
- Leerink Partners reiterated its buy rating on Eli Lilly (NYSE: LLY) with a price target of $1,232 on June 25, 2026.
- Leerink Partners's $1,232 price target implies 1.98% upside from Eli Lilly and Company's ($LLY) current $1,208.12 share price.
- Shares traded near $1,117.26 on Thursday with a market cap of about $982.8 billion and a P/E ratio of 39.19.
- Insider buying occurred on June 15, 2026, with small purchases by several insiders at around $1,129.35 per share.
Get $LLY trade alerts by text
We text you when insiders, Congress or big funds trade $LLY. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Eli Lilly and Company alert may contain errors. Disclosures
On June 25, 2026, Leerink Partners reiterated its buy rating on Eli Lilly and Company (NYSE: LLY), setting a price target of $1,232. This decision comes as shares of Eli Lilly traded near $1,117.26 on Thursday.
Leerink Partners vs. the S&P 500
Hypothetical returns from Leerink Partners's disclosed trades, not real profit or advice. How we model this.
Analysts Set New Price Targets
On June 25, 2026, Leerink Partners maintained its buy rating for Eli Lilly, setting a price target of $1,232. This follows similar sentiments from other analysts like Jefferies, which maintained a buy rating with a $1,350 target on June 9, 2026. B of A Securities also kept a buy rating with a $1,251 target on May 26, 2026, while Barclays set a price target of $1,400 on May 5, 2026, maintaining its buy stance.
Eli Lilly and Company Stock Down 0.1%
Shares of Eli Lilly (NYSE: LLY) traded near $1,117.26 on Thursday. The company boasts a substantial market cap of approximately $982.8 billion. Eli Lilly has a price-to-earnings ratio of 39.19 and a forward P/E of 24.79. The stock has seen a 52-week low of $623.78 and a high of $1,182.73, with a 50-day moving average of $1,011.09 and a 200-day moving average of $966.09. The company maintains a current ratio of 1.50 and a debt-to-equity ratio of 139.02.
$LLY price target
Eli Lilly and Company daily closes and this analyst's $1,232 target. Not advice.
Insider Buying and Selling at Eli Lilly and Company
Insider activity at Eli Lilly has been notable, with several small purchases occurring on June 15, 2026. Luciano Juan, Erik Fyrwald, Ralph Alvarez, and Gabrielle Sulzberger bought 14, 9, 11, and 4 shares, respectively, at an average price of $1,129.35. Additionally, Ilya Yuffa, EVP & Pres, LLY USA & Global Capabilities, sold 2,500 shares at $1,150.77 on June 10, 2026, in a planned transaction.
About Eli Lilly and Company
Eli Lilly and Company, headquartered in Indianapolis, Indiana, is a global healthcare leader in the pharmaceutical industry. The company, led by CEO Mr. David A. Ricks, employs around 50,000 people. It develops and markets a wide range of human pharmaceutical products, including treatments for diabetes, oncology, immunology, and more. With a history dating back to 1876, Eli Lilly continues to innovate in the healthcare sector.
Bottom Line
Leerink Partners' reiteration of its buy rating for Eli Lilly with a $1,232 price target underscores the firm's confidence in the company's future prospects. Investors often track analyst ratings for insights into potential stock movements. However, it's important to remember that such ratings represent a snapshot in time and may not reflect future changes in market conditions.
Related Filing Alerts
Source: Leerink Partners's rating change on $LLY (Jun 25, 2026). Written by software, not financial advice. How we make alerts